Health Robotics’ CytoCare(TM) Global Expansion Continues With Grifols International in Latin America

BOZEN, Italy, October 5 /PRNewswire/ — Health Robotics today announced
that it has signed an exclusive five-year strategic partnership with Grifols
International S.A. for its revolutionary CytoCare Robot. The agreement
enables Grifols to add CytoCare to its prior i.v.STATION(TM) contract with
Health Robotics, and achieve its objective to safely, accurately and
cost-effectively automate the preparation of Oncology I.V. Admixtures in
Mexico, Chile, Brazil, Argentina, Uruguay, Paraguay, Bolivia, Peru,
Venezuela, Colombia, Ecuador, Panama, Costa Rica, Belize, Nicaragua, El
Salvador, Honduras, Guatemala, Surinam, French Guyana, and Guyana. In
addition, the contract between the companies also adds Mexico to Grifols’
i.v.STATION distribution and support rights after Health Robotics recently
accomplished the termination of its last Devon Robotics contract.

While other companies have for many years made promises of robotic IV
automation products, and even showcased marketing demonstrations of competing
solutions that were supposed to exist as far back as twenty years ago[1], the
fact remains that CytoCare is the only available solution that currently
exists anywhere in the world to automatically compound and prepare
ready-to-administer hazardous IV Admixtures for Oncology and other drug
classes, and that has been proven to work in a “live” hospital pharmacy
environment, instead of just marketing hype, sales brochures, and “staged”
demonstrations at pharmaceutical trade symposiums such as ASHP and EAHP.

“We are very excited to have been chosen by Health Robotics as their
exclusive CytoCare partner in Latin America, and to add one of the largest
Latin American markets [Mexico] to our i.v.STATION distribution rights.
CytoCare, the world’s first and only robotic system designed for the safe and
sterile preparation of patient-specific hazardous IV Admixtures, represents
an ideal complement to our other market-leading Pharmacy Automation products.
Health Robotics’ two products will help our local service teams in Latin
America differentiate our pharmacy solutions from both clinical and financial
perspectives”, stated Xavier Guix, VP of Marketing for Grifols’ Hospital
System Division”.

“Grifols is the perfect fit for Health Robotics in Latin America due to
their well-established distribution channels, their commitment to patient
safety, their company stability and superior market footprint, and finally
their world-class service infrastructure. In addition to the obvious success
in expanding our partnership with Grifols and receiving a repeat endorsement
from an existing Health Robotics’ partner, I’m very pleased that this new
contract symbolizes three significant milestones for Health Robotics: the
final replacement of Devon as a local service provider for Health Robotics,
the irrevocable termination of all contractual arrangements between the Devon
International Group and Health Robotics, and lastly, the rapid and successful
attainment of 95% distribution and support global coverage for our CytoCare
robot, much needed after Devon’s attempted disruptions to our customers due
to their many litigations with their former financial partners in America and
in Asia, such as HRNA and ITOCHU”, stated Werner Rainer, Health Robotics’ CEO

About Health Robotics:

Health Robotics is the global leading supplier of life-critical
intra-venous medication preparation, compounding, and dispensing Robots,
providing healthcare facilities in four continents with robotics technology
and software automation solutions. The world-leading solutions CytoCare
[hazardous IVs], i.v.STATION [non-hazardous IVs], i.v.SOFT [workflow engine]
and the future development of TPNstation, have and will greatly contribute to
ease global hospitals’ growing pressures to improve patient safety through
the effective and efficient production of sterile, accurate, and
ready-to-administer IVs, to eliminate life-threatening drug-exchange errors,
to decrease other medication errors and sterility risks, and to work more
efficiently, increase throughput, reduce waste, and contain costs. For more
information, please visit http://www.health-robotics.com

About Grifols:

Grifols International is a Spain-based company engaged in the healthcare
sector and is listed on Ibex-35 stock market. Grifols is involved in the
research, development, manufacturing and marketing of plasma derivates, IV
therapy solutions, enteral and parenteral nutrition, diagnostic systems,
pharmacy automation, and medical materials and devices. Founded in 1940,
Grifols currently operates in 90 countries with more than 6.000 employees, 26
subsidiaries with combined gross revenues over EUR800 million, and a EUR3
billion market capitalization. For more information, please visit
http://www.grifols.com

    [1] Am J Hosp Pharm 46(11): 2286-93 1989
    ---------------------------------

    For additional information, please contact:
    Health Robotics S.r.l.
    Gaspar G. DeViedma
    Altmanstrasse 9A, Bozen, Sud-Tyrol, I-39100
    USA: +1-609-980-7976
    EUROPE: +39-346-963-4934
    gaspar.deviedma@health-robotics.com

    Grifols Internacional S.A.
    Raquel Lumbreras
    Gabinete de Prensa Grifols
    Europe: +34-91-311-9289 / +34-91-221-7448 / +34-659-572-185
    Raquel_lumbreras@duomocomunicacion.com

SOURCE Health Robotics SRL